Trial Profile

ImmunTraCkeR testing before and during treatment with ipilimumab in patients with metastatic melanoma

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 06 Aug 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary)
Indications Malignant melanoma
Focus Biomarker; Pharmacodynamics
Acronyms PREDICT-ID
Sponsors ImmunID

Most Recent Events

16 Dec 2014 New trial record
10 Dec 2014 This study has been authorised by French regulatory bodies and is expected to start in January 2015, according to an ImmunID media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com